Tim Read, Ph.D., BS (he/him/his)

Arpeggio Biosciences, Colorado, United States

Tim Read is a creative and collaborative molecular biologist with extensive drug discovery experience. As Co-founder and Chief Technology Officer at Arpeggio Biosciences, his role includes conceptualizing and implementing novel technologies that measure how drugs interact with entire genomes and the biological networks that underlie disease. Prior to Arpeggio, Tim was an NIH/NIGMS post-doctoral fellow in the laboratory of Dr. Martha Bulyk at Harvard Medical School and Brigham and Women’s Hospital in Boston, MA studying how transcription factor binding affects enhancer-mediated transcriptional regulation. Prior to graduate school, Tim worked as a research associate at Alnylam Pharmaceuticals where he participated in early research on the recently approved drug, Inclisiran (Leqvio).

Disclosure information not submitted.

Presentation(s):

• Development of a Global Reporter on Transcript Abundance (GRETA) for drug discovery and development

  Monday, February 5, 2024
  12:00 PM – 1:00 PM EST